Behandling med inhalationssteroid øger risiko for pneumoni ved kronisk obstruktiv lungesygdom

Mads Lumholdt; Janni Vagner Steenholt; Jørgen Vestbo

Behandling med inhalationssteroid øger risiko for pneumoni ved kronisk obstruktiv lungesygdom

Translated title of the contribution: Inhaled corticosteroid treatment increases the risk of pneumonia in patients with CPOD

Mads Lumholdt, Janni Vagner Steenholt, Jørgen Vestbo

Research output: Contribution to journal › Journal article › Research › peer-review

1 Citation (Scopus)

Abstract

Clinical studies have suggested that inhaled corticosteroid (ICS) increases the frequency of pneumonia in patients with chronic obstructive pulmonary disease (COPD). This article summarizes the risk of pneumonia by reviewing the largest clinical studies addressing pneumonia as an adverse effect of ICS treatment. The collected data show that treatment of COPD patients with ICS increases the rate of pneumonia compared with b2-agonists or placebo. Physicians are recommended to follow guidelines and solely treat COPD patients with ICS if the patients are at high risk of exacerbations.

Translated title of the contribution	Inhaled corticosteroid treatment increases the risk of pneumonia in patients with CPOD
Original language	Danish
Article number	V03140137
Journal	Ugeskrift for Laeger
Volume	176
Pages (from-to)	1700-1703
Publication status	Published - 1 Sept 2014
Externally published	Yes

Keywords

English Abstract
Journal Article

Access to Document

http://ugeskriftet.dk/videnskab/V03140137

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{fb9230ca53be4d99be0107a51e769adb,

title = "Behandling med inhalationssteroid {\o}ger risiko for pneumoni ved kronisk obstruktiv lungesygdom",

abstract = "Inhaled corticosteroid treatment increases the risk of pneumonia in patients with COPD.Clinical studies have suggested that inhaled corticosteroid (ICS) increases the frequency of pneumonia in patients with chronic obstructive pulmonary disease (COPD). This article summarizes the risk of pneumonia by reviewing the largest clinical studies addressing pneumonia as an adverse effect of ICS treatment. The collected data show that treatment of COPD patients with ICS increases the rate of pneumonia compared with β2-agonists or placebo. Physicians are recommended to follow guidelines and solely treat COPD patients with ICS if the patients are at high risk of exacerbations.",

keywords = "English Abstract, Journal Article",

author = "Mads Lumholdt and Steenholt, {Janni Vagner} and J{\o}rgen Vestbo",

note = "Blad nummer: 18/2015",

year = "2014",

month = sep,

day = "1",

language = "Dansk",

volume = "176",

pages = "1700--1703",

journal = "Ugeskrift for Laeger",

issn = "1399-4174",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Behandling med inhalationssteroid øger risiko for pneumoni ved kronisk obstruktiv lungesygdom

AU - Lumholdt, Mads

AU - Steenholt, Janni Vagner

AU - Vestbo, Jørgen

N1 - Blad nummer: 18/2015

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Inhaled corticosteroid treatment increases the risk of pneumonia in patients with COPD.Clinical studies have suggested that inhaled corticosteroid (ICS) increases the frequency of pneumonia in patients with chronic obstructive pulmonary disease (COPD). This article summarizes the risk of pneumonia by reviewing the largest clinical studies addressing pneumonia as an adverse effect of ICS treatment. The collected data show that treatment of COPD patients with ICS increases the rate of pneumonia compared with β2-agonists or placebo. Physicians are recommended to follow guidelines and solely treat COPD patients with ICS if the patients are at high risk of exacerbations.

AB - Inhaled corticosteroid treatment increases the risk of pneumonia in patients with COPD.Clinical studies have suggested that inhaled corticosteroid (ICS) increases the frequency of pneumonia in patients with chronic obstructive pulmonary disease (COPD). This article summarizes the risk of pneumonia by reviewing the largest clinical studies addressing pneumonia as an adverse effect of ICS treatment. The collected data show that treatment of COPD patients with ICS increases the rate of pneumonia compared with β2-agonists or placebo. Physicians are recommended to follow guidelines and solely treat COPD patients with ICS if the patients are at high risk of exacerbations.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 25293857

SN - 1399-4174

VL - 176

SP - 1700

EP - 1703

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V03140137

ER -

Behandling med inhalationssteroid øger risiko for pneumoni ved kronisk obstruktiv lungesygdom

Abstract

Keywords

Access to Document

AUB Link

Fingerprint

Cite this